Form 4: Amphastar Pharmaceuticals Executive Rong Zhou Reports Stock Transactions

Senior EVP Rong Zhou of Amphastar Pharmaceuticals reports exercising stock options and selling shares on September 13, 2024.

Summary

• On September 13, 2024, Rong Zhou, Senior EVP of Production Center at Amphastar Pharmaceuticals, exercised employee stock options to acquire 3,000 shares of common stock at $14.95 per share.
• On the same day, Zhou sold 3,000 shares of common stock at $48.2615 per share.
• Following these transactions, Zhou directly owns 118,388 shares of common stock.
• Zhou also indirectly owns 99,668 shares through the Zhou Family Trust and 5,000 shares held by his spouse.
• Zhou directly owns options to purchase 6,893 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of stock transactions. The exercise and sale could be for various personal financial reasons and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Insider trading activity is closely monitored in the pharmaceutical industry, similar to other sectors, to ensure fair market practices.
• Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Pfizer also have executives who regularly file Form 4s, reflecting the common nature of stock-based compensation and trading activities.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
• The filing provides transparency to stakeholders regarding insider trading activities.

Key Dates